About Us

The frustration of battling an invisible disease like chronic pain can leave you feeling isolated and hopeless. Over-the-counter remedies do nothing more than numb the skin, providing little to no relief, and opioids can take you down a scary path. This is something Nex-Zol Pharma’s founders are all too familiar with.

Joe Fracassi, Tom Scarlata and Joel Carden have all grappled with intimate life connections to pain. Joe watched his father desperately struggle with chronic pain in the final years of his life, finding little to no relief with over-the-counter remedies. In sharing his story with Tom, a pharmaceutical executive who had spent decades developing prescription medicines, and Joel, a sales and marketing expert, Nex-Zol Pharma was created.
After decades of watching people struggling with muscle and joint pain fail to find relief with over-the-counter-products or prescription drugs, Joe, Tom and Joel knew they wanted to create a product rooted in sound science that would not only become a trusted source of natural relief, but could also enhance your general well-being in a reliable and ethical way.

Nex-Zol Pharma’s journey began with this one simple thought:
What if we could make a topical that actually penetrates the skin and reaches the source of most people’s discomfort?
With more than a combined 100 years of experience and having provided products to millions of people, we set out to create an effective alternative-relief topical.

About Phyto-ZOL® CBD

Through two years of innovation, hard work and putting science first, our team of experts created a revolutionary delivery technique called ZOL, clinically proven to penetrate through layers of skin and reach deep into the muscles and joints. The search for the safest non-addictive natural relief topical we could find led to the micro-encapsulated CBD. Thus, Phyto-ZOL® CBD, our breakthrough patented transdermal topical serum using only the highest-grade ingredients, was born.

What initially started as a remedy for chronic pain has evolved into so much more. With Phyto-ZOL® CBD, we’re able to not only help those who suffer from chronic pain, but we’re also helping those who have a vested interest in enhancing their overall wellness in a natural way.

Today, Phyto-ZOL® is the preferred transdermal topical CBD of health care professionals, delivering more active relief faster than other topicals, and we’re very proud of that.

But seeing real stories from real people who have tried and failed with all the other options before finding relief with Phyto-ZOL® CBD gratifies us the most, because at the end of the day, our goal has always been to help as many people as we can lead a better quality of life.


Purchase Now

About Nex-Zol’s Founders


Joe Fracassi began his career in the chemical services industry, where he held management positions at EG&G Corporation and Mobil Oil Corporation. In 1981, Joe joined Pacific World, holding roles such as Sales Manager and Vice President of Sales and Marketing. In 1992, Joe was appointed President of Pacific World. Joe served as President for 22 years, and under his leadership, Pacific World grew from a $4 million business to a $250 million corporation. Joe received his bachelor of science degree in business administration from California State University at Northridge.


Joel Carden began his career in the world of health and beauty products, holding various titles with the following companies: Redmond Products, Revlon Products, L’Oréal Cosmetics and Fragrance Division, and the Noxell Corporation. In 1995, Joel joined Pacific World as Vice President of Sales for the U.S. market, later expanding his role to Vice President of Global Sales in 1997. Starting in 2005, Joel served as Executive Vice President of Sales and Marketing for Pacific World, and alongside Joe Fracassi, helped grow Pacific World to a $250 million corporation.


Tom begin his career at Warner-Lambert (Parke-Davis/Pfizer), where he held increasing levels of responsibility in Sales, Market Research, Advertising, Global Marketing, Regional Management and U.S. Brand Leadership for $1 billion brands. Tom then entered into the specialty pharmaceutical market with Allergan, where he transitioned a $120 million product portfolio to a newly created contract sales organization and drove the commercial development of a new fourth-generation ophthalmic anti-infective. With over 30 years of senior-level pharmaceutical business experience with global and specialty pharmaceutical companies, Tom has held a broad range of roles in commercialization of pharmaceutical brands across multiple therapeutic categories, including launching key brands in diabetes, pain, gastroenterology, cardiology, Alzheimer’s disease, ophthalmology and oncology. Most recently, Tom consulted in a variety of roles, including Executive Vice President of Commercialization for a startup pharmaceutical company and for a local pharmaceutical advertising and PR company. He also owned and operated his own pharmacy-supply business. Tom graduated from the Philadelphia College of Pharmacy with a bachelor of science in pharmacy and holds an MBA in finance from Drexel University.